| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
75,630,000 |
| Market
Cap: |
6.81(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$34.89 - $97.01 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Merus is a clinical-stage oncology company developing antibody therapeutics. Using its Biclonics® platform, Co. has produced and is developing the following candidates: MCLA-128 (zenocutuzumab) for the treatment of solid tumors that harbor Neuregulin 1 gene fusions; MCLA-117 for the treatment of acute myeloid leukemia; MCLA-158 for the treatment of solid tumors; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors and a hematological malignancy, B-cell lymphoma. Co. is also developing a late-stage pre-clinical candidate, MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd., for the potential treatment of solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,421,216 |
2,421,216 |
2,421,216 |
2,421,216 |
| Total Buy Value |
$234,857,952 |
$234,857,952 |
$234,857,952 |
$234,857,952 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
10 |
10 |
10 |
10 |
| Total Shares Sold |
75,875,499 |
75,875,499 |
75,961,999 |
76,053,299 |
| Total Sell Value |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
3 |
3 |
| Total Sell Transactions |
2 |
2 |
7 |
14 |
| End Date |
2025-11-02 |
2025-08-01 |
2025-01-31 |
2024-02-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Genmab A/s |
|
– – • |
2025-12-29 |
4 |
S |
$97.00 |
$2,147,483,647 |
I/I |
(75,867,199) |
0 |
|
- |
|
| Genmab A/s |
|
– – • |
2025-12-29 |
4 |
B |
$97.00 |
$102,122,182 |
I/I |
1,052,806 |
73,884,293 |
0.01 |
- |
|
| Genmab A/s |
|
– – • |
2025-12-26 |
4 |
B |
$97.00 |
$288,866 |
I/I |
2,978 |
72,831,487 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-26 |
4 |
B |
$97.00 |
$13,833,170 |
I/I |
142,610 |
72,828,509 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-24 |
4 |
B |
$97.00 |
$9,319,954 |
I/I |
96,082 |
72,685,899 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-23 |
4 |
B |
$97.00 |
$54,421,074 |
I/I |
561,042 |
72,589,817 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-22 |
4 |
B |
$97.00 |
$1,523,870 |
I/I |
15,710 |
72,028,775 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-19 |
4 |
B |
$97.00 |
$6,427,608 |
I/I |
66,264 |
72,013,065 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-18 |
4 |
B |
$97.00 |
$20,581,169 |
I/I |
212,177 |
71,946,801 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-17 |
4 |
B |
$97.00 |
$14,627,115 |
I/I |
150,795 |
71,734,624 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-16 |
4 |
B |
$97.00 |
$11,712,944 |
I/I |
120,752 |
71,583,829 |
0.01 |
-7% |
|
| Genmab A/s |
|
– – • |
2025-12-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
71,463,077 |
|
-7% |
|
| Shuman Harry |
VP Controller, PAO |
• – – |
2025-12-12 |
4 |
D |
$97.00 |
$1,067,194 |
D/D |
(11,002) |
0 |
|
- |
|
| Iwicki Mark T |
|
– • – |
2025-12-12 |
4 |
D |
$97.00 |
$7,136,872 |
D/D |
(73,576) |
0 |
|
- |
|
| Lundberg Sven Ante |
President, CEO & PEO |
• • – |
2025-12-12 |
4 |
D |
$97.00 |
$8,093,195 |
I/I |
(83,435) |
0 |
|
- |
|
| Lundberg Sven Ante |
President, CEO & PEO |
• • – |
2025-11-25 |
4 |
GA |
$0.00 |
$0 |
I/I |
40,452 |
9,192 |
|
- |
|
| Lundberg Sven Ante |
President, CEO & PEO |
• • – |
2025-11-25 |
4 |
GD |
$0.00 |
$0 |
I/I |
125,460 |
16,372 |
|
- |
|
| Lundberg Sven Ante |
President, CEO & PEO |
• • – |
2025-11-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,297 |
0 |
|
- |
|
| Shuman Harry |
VP Controller, PAO |
• – – |
2025-11-25 |
4 |
S |
$95.92 |
$796,136 |
D/D |
(8,300) |
11,002 |
|
6% |
|
| Shuman Harry |
VP Controller, PAO |
• – – |
2025-11-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,300 |
19,302 |
|
- |
|
| Silverman Peter B. |
COO & GC |
• – – |
2025-07-17 |
4 |
AS |
$60.00 |
$1,500,000 |
D/D |
(25,000) |
0 |
|
56% |
|
| Silverman Peter B. |
COO & GC |
• – – |
2025-07-17 |
4 |
OE |
$24.43 |
$610,750 |
D/D |
25,000 |
25,000 |
|
- |
|
| Silverman Peter B. |
COO & GC |
• – – |
2025-07-10 |
4 |
AS |
$55.00 |
$924,275 |
D/D |
(16,805) |
0 |
|
74% |
|
| Silverman Peter B. |
COO & GC |
• – – |
2025-07-10 |
4 |
OE |
$18.61 |
$312,741 |
D/D |
16,805 |
16,805 |
|
- |
|
| Silverman Peter B. |
COO & GC |
• – – |
2025-07-09 |
4 |
AS |
$55.00 |
$368,225 |
D/D |
(6,695) |
0 |
|
76% |
|
157 Records found
|
|
Page 1 of 7 |
|
|
